Empress Therapeutics
Xiaorui Guo began their work experience at the University of Illinois Urbana-Champaign in October 2014 as a Ph.D. Candidate and completed their role in December 2020. They later joined Empress Therapeutics in January 2021 as a Scientist and was promoted to Scientist II in March 2022.
Xiaorui Guo completed a Bachelor of Science (B.S.) degree in Chemical Biology from the University of California, Berkeley from 2010 to 2014. Following this, from 2014 to 2020, Xiaorui pursued a Doctor of Philosophy (PhD) degree in Natural Products Chemistry and Pharmacognosy at the University of Illinois Urbana-Champaign.
Empress Therapeutics
Founded by Flagship Pioneering, Empress re-imagines the process of small molecule drug discovery. Our bioplatform harnesses the power of evolution, human molecular and genetic data, and artificial intelligence to focus on endogenous sources of inherently drug-like small molecules as a uniquely qualified source of potential drugs. Our mission is to generate transformative drug candidates that get to the clinic faster and cheaper, with a higher probability of success.